ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AKRO

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Akero Therapeutics, Inc. common stock during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Akero common stock between September 13, 2022, and October 9, 2023, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by June 25, 2024 [1][4]. Group 2: Case Allegations - The lawsuit alleges that Akero made false and misleading statements regarding the SYMMETRY study, which tested its lead product candidate, efruxifermin (EFX), in patients with Non-alcoholic Steatohepatitis (NASH) induced cirrhosis [3]. - Key allegations include that approximately 20% of patients in the SYMMETRY study had cryptogenic cirrhosis and did not have definitive NASH at baseline, which was not disclosed [3]. - The lawsuit claims that the results from these patients were improperly included in the study, potentially skewing the results and increasing the risk of failing to meet the primary endpoint [3]. - It is also alleged that Akero did not align the study with U.S. FDA guidance, further misrepresenting the trial's nature and its potential success in supporting a new drug application [3].